[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)

TABLE OF CONTENTS

1              Introduction

1.1          Market Definition

1.2          Market Scope

2              Research Methodology

2.1          Primary Research

2.2          Research Methodology

2.3          Assumptions & Exclusions

2.4          Secondary Data Sources

3              Market Overview

3.1          Report Segmentation & Scope

3.2          Value Chain Analysis: Oncology Biosimilar Market

3.3          Key Market Trends

3.3.1      Drivers

3.3.2      Restraints

3.3.3      Opportunities

3.4          Porter’s Five Forces Analysis

3.4.1      Bargaining Power of Suppliers

3.4.2      Bargaining Power of Buyers

3.4.3      Threat of Substitution

3.4.4      Threat of New Entrants

3.4.5      Competitive Rivalry

3.5          Market Share Analysis

4              By Types of Cancer

4.1          Introduction

4.1.1      Market Size & Forecast (Value)

4.2       Breast Cancer

4.3       Colorectal Cancer

4.4       Blood Cancer

4.5       Neutropenia Cancer

       4.6       Non-Small Cell Lung Cancer

5              By Drug Type

5.1          Introduction

5.1.1      Market Size & Forecast (Value)

5.2      mAb

5.3      Immunomodulators

5.4      Hematopoietic agents

5.5      G-CSF

5.6      Others

6              Regional Overview

6.1          Introduction

6.1.1      Market Size & Forecast (Value)

6.2          America

6.2.1      North America

6.2.1.1   U.S.

6.2.1.1.1               By Types of Cancer

6.2.1.1.2              By Drug Type  

6.2.1.2   Canada

6.2.1.2.1               By Types of Cancer

6.2.1.2.2               By Drug Type  

6.2.1.3   Mexico

6.2.1.3.1               By Types of Cancer

6.2.1.1.2              By Drug Type  

6.2.2      Latin America

6.2.2.1                   By Types of Cancer

6.2.2.2                  By Drug Type  

6.3          Europe

6.3.1      Market Size & Forecast (Value)

6.3.2      Germany

6.3.2.1                   By Types of Cancer

6.3.2.2                 By Drug Type  

6.3.3      France

6.3.3.1                   By Types of Cancer

6.3.3.2                   By Drug Type  

6.3.4      U.K.

6.3.4.1                   By Types of Cancer

6.3.4.2                   By Drug Type  

6.3.5      Italy

6.3.5.1                   By Types of Cancer

6.3.5.2                   By Drug Type  

6.3.6      Spain

6.3.6.1                   By Types of Cancer

6.3.6.2                   By Drug Type  

6.3.7      Rest of Europe

6.3.7.1                   By Types of Cancer

6.3.7.2                  By Drug Type  

6.4          Asia Pacific

6.4.1      Market Size & Forecast (Value)

6.4.2      Japan

6.4.2.1                   By Types of Cancer

6.4.2.2                 By Drug Type  

6.4.3      China

6.4.3.1                   By Types of Cancer

6.4.3.2                  By Drug Type  

6.4.4      Australia

6.4.4.1                   By Types of Cancer

6.4.4.2                   By Drug Type  

6.4.5      India

6.4.5.1                   By Types of Cancer

6.4.5.2                 By Drug Type  

6.4.6      South Korea

6.4.6.1                   By Types of Cancer

6.4.6.2                 By Drug Type  

6.4.7      Rest of Asia-Pacific

6.4.7.1                   By Types of Cancer

6.4.7.2                   By Drug Type  

6.5          Middle East & Africa

6.5.1      Market Size & Forecast (Value)

6.5.2      Saudi Arabia

6.5.2.1                   By Types of Cancer

6.5.2.2                   By Drug Type  

6.5.3      South Africa

6.5.3.1                   By Types of Cancer

6.5.3.2                 By Drug Type  

6.5.4      Kuwait

6.5.4.1                   By Types of Cancer

6.5.4.2                 By Drug Type  

6.5.5      Rest of Middle East & Africa

6.5.5.1                   By Types of Cancer

6.5.5.2                 By Drug Type  

7.            Company Profile

7.1          Teva Pharmaceutical Industries Ltd.

7.1.1      Company Overview

7.1.2      Financial Performance

7.1.3      Recent Developments

7.1.4      Product Portfolio

7.2          Biocon

7.2.1      Company Overview

7.2.2      Financial Performance

7.2.3      Recent Developments

7.2.4      Product Portfolio

7.3          STADA Arzneimittel AG

7.3.1      Company Overview

7.3.2      Financial Performance

7.3.3      Recent Developments

7.3.4      Product Portfolio

7.4          Sandoz International GmbH

7.4.1      Company Overview

7.4.2      Financial Performance

7.4.3      Recent Developments

7.4.4      Product Portfolio

7.5          Intas Pharmaceuticals Ltd.

7.5.1      Company Overview

7.5.2      Financial Performance

7.5.3      Recent Developments

7.5.4      Product Portfolio

7.6          Celltrion Inc.

7.6.1      Company Overview

7.6.2      Financial Performance

7.6.3      Recent Developments

7.6.4      Product Portfolio

7.7          Pfizer Inc.

7.7.1      Company Overview

7.7.2      Financial Performance

7.7.3      Recent Developments

7.7.4      Product Portfolio

7.8          Apotex Inc.

7.8.1      Company Overview

7.8.2      Financial Performance

7.8.3      Recent Developments

7.8.4      Product Portfolio

7.9          Dr. Reddy’s Laboratories Ltd.

8.9.1      Company Overview

7.9.2      Financial Performance

7.9.3      Recent Developments

7.9.4      Product Portfolio

7.10        BIOCAD

7.10.1    Company Overview

7.10.2    Financial Performance

7.10.3    Recent Developments

7.10.4    Product Portfolio



Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports